https://scholars.lib.ntu.edu.tw/handle/123456789/383115
標題: | A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs | 作者: | Funch, D. Kin-Wei Chan Gydesen, H. Tornoe, K. Major-Pedersen, A. Chan, K. A. |
關鍵字: | GLP-1; Observational study; Pharmaco-epidemiology | 公開日期: | 2014 | 卷: | 16 | 期: | 3 | 起(迄)頁: | 273-275 | 來源出版物: | Diabetes, Obesity and Metabolism | 摘要: | Aim: We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme. Methods: Initiators of liraglutide, exenatide, metformin, pioglitazone or groups containing initiators of dipeptidyl peptidase-4 inhibitors or sulfonylureas were identified in a US commercial health insurance claims database (1 February 2010 to 31 March 2013) and followed for a median of 15months. We estimated incidence rates (IR/100 000 person-years), rate ratio (RR) and 95% confidence intervals (CI) of new insurance claims with diagnoses of primary inpatient acute pancreatitis or pancreatic cancer from Poisson regression models. Results: The IR for acute pancreatitis for liraglutide was 187.5 compared with 154.4 for all non-glucagon-like peptide-1 (GLP-1)-based therapies (adjusted RR 1.10; CI 0.81-1.49). The IR for pancreatic cancer was 19.9 for liraglutide compared with 33.0 for all non-GLP-1-based therapies (adjusted RR 0.65; 95% CI 0.26-1.60). Conclusion: We did not observe excess risk of either outcome associated with liraglutide relative to individual or pooled comparator drugs. ? 2013 John Wiley & Sons Ltd. |
URI: | http://www.scopus.com/inward/record.url?eid=2-s2.0-84893813443&partnerID=MN8TOARS http://scholars.lib.ntu.edu.tw/handle/123456789/383115 |
DOI: | 10.1111/dom.12230 | SDG/關鍵字: | antidiabetic agent; glucagon like peptide 1 receptor agonist; liraglutide; metformin; pioglitazone; sulfonylurea; acute pancreatitis; adult; article; cancer risk; confidence interval; diabetes mellitus; disease association; disease severity; drug safety; female; follow up; health care utilization; health insurance; human; incidence; intention to treat analysis; major clinical study; male; multivariate analysis; non insulin dependent diabetes mellitus; pancreas cancer; Poisson distribution; postmarketing surveillance; prospective study; risk assessment; treatment outcome; GLP-1; observational study; pharmaco-epidemiology; Databases, Factual; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insurance Claim Reporting; Insurance, Health; Male; Metformin; Pancreatic Neoplasms; Pancreatitis; Prospective Studies; Risk Assessment; Sulfonylurea Compounds; United States |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。